论文部分内容阅读
本文采用HPLC法同时测定血浆中复方磺胺甲噁唑吐分散片中SMZ和TMP的浓度,采用HypersilODS柱,流动相为乙腈:醋酸钠(pH6.4 0.lmol/L)=22:78(V/V),检测波长230nm,流速为1.00ml/min.10名志愿受试者自身交叉口服Go-SMZ片和Co-SMZ分散片800mg,结果显示SMZ和TMP的Cmax分别为46.69±7.66μg/ml,44.61±6.37μg/ml和1.82±0.49μg/ml,1.63±0.43μg/ml;Tmax为3.41±1.59h,3.4±0.84h和1.48±0.83h,1.50±0.81h;AUC为761±l29.37μg.h/ml,761.79±145.6μg.h/ml和26.91±3.89μg.h/ml,26.96±4.7lμg.h/ml.分散片中SMZ和TMP相对于参比制剂的相对生物利用度分别为101.28±14.35%,101.26±15.76%.
In this paper, simultaneous determination of SMZ and TMP in compound sulfamethoxazole dispersible tablets by HPLC was carried out on a Hypersil ODS column with a mobile phase of acetonitrile: sodium acetate (pH6.4 0.lmol / L) = 22:78 (V / V), the detection wavelength was 230nm, the flow rate was 1.00ml / min.10 volunteers crossed with self-administered Go-SMZ tablets and Co-SMZ dispersible tablets 800mg. The results showed that the Cmax of SMZ and TMP were 46.69 ± 7.66μg / ml, 44.61 ± 6.37μg / ml and 1.82 ± 0.49μg / ml, 1.63 ± 0.43μg / ml respectively; Tmax was 3.41 ± 1.59h, 3.4 ± 0.84h and 1.48 ± 0.83h, 1.50 ± 0.81h; AUC was 761 ± l29 761.79 ± 145.6 μg.h / ml, and 26.91 ± 3.89 μg.h / ml, 26.96 ± 4.7 lμg.h / ml The relative bioavailability of SMZ and TMP relative to the reference formulation in the dispersible tablets Respectively 101.28 ± 14.35% and 101.26 ± 15.76%.